The global pulmonary embolism market is valued at USD 2.41 billion in 2025 and is projected to surge from USD 2.66 billion in 2026 to approximately USD 5.10 billion by 2033, registering a robust CAGR of 10.3% over the forecast period. Rising incidence of venous thromboembolism, accelerating adoption of direct oral anticoagulants (DOACs), and the integration of artificial intelligence into diagnostic workflows are collectively reshaping the treatment landscape. North America commands the largest revenue share, while Asia-Pacific emerges as the fastest-growing region driven by expanding healthcare infrastructure and growing patient awareness. Landmark clinical approvals, strategic pharmaceutical partnerships, and evolving interventional procedures are further reinforcing market momentum across developed and emerging economies.
HOUSTON, Texas, United States, June 2026 -
The global burden of pulmonary embolism (PE) has reached a critical inflection point. Every year, millions of patients worldwide are diagnosed with life-threatening blood clots in the pulmonary arteries - a condition that, if left untreated, carries a mortality rate exceeding 30%. Today, the convergence of novel therapeutics, precision diagnostics, and technology-enabled care pathways is fundamentally transforming how clinicians identify, manage, and prevent this deadly disease.
Against this clinical backdrop, the pulmonary embolism market is on a high-growth trajectory. Valued at USD 2.41 billion in 2025, the market is forecast to nearly double to USD 5.10 billion by 2033, expanding at a CAGR of 10.3%. This remarkable growth story is underpinned by multiple forces - demographic aging, improved PE awareness campaigns, growing adoption of mechanical thrombectomy devices, and an expanding pipeline of next-generation anticoagulants poised to redefine standard of care.
Fortune Data Vista has published an in-depth industry intelligence report capturing these trends, competitive dynamics, and strategic opportunities shaping the global pulmonary embolism market through 2033.
Why the Pulmonary Embolism Market Is Entering a New Growth Era
The rising prevalence of risk factors - including prolonged immobility, cancer-associated thrombosis, obesity, and post-surgical complications - continues to expand the global PE patient pool. Pulmonary embolism response teams (PERTs), now widely adopted across leading hospitals in North America and Europe, have dramatically improved multidisciplinary care coordination, accelerating time-to-treatment and reducing in-hospital mortality.
At the therapeutic front, DOACs such as apixaban (Eliquis), rivaroxaban (Xarelto), and edoxaban (Savaysa) have effectively displaced traditional vitamin K antagonists as the first-line treatment choice, owing to their predictable pharmacokinetics, reduced bleeding risk, and patient-friendly oral administration. This paradigm shift toward DOACs continues to be a powerful revenue driver, with pharmaceutical giants including Pfizer, Bristol-Myers Squibb, and Bayer AG leading the commercial charge.
Simultaneously, catheter-directed thrombolysis and mechanical thrombectomy - championed by medical device innovators such as Inari Medical and Boston Scientific - are gaining traction in intermediate and high-risk PE cases, opening a high-value procedural revenue stream alongside pharmacological therapies.
🔍 Unlock the Full Market Intelligence Report - Explore Detailed Data, Forecasts & Competitive Benchmarks
Download Your Free Sample Report Now →
https://www.fortunedatavista.com/sample/1102
Competitive Landscape: Who Is Dominating the Pulmonary Embolism Market?
Pfizer Inc. / Bristol-Myers Squibb (BMS) - Eliquis (Apixaban) Leadership
The Pfizer-BMS alliance behind Eliquis has cemented market leadership with apixaban being one of the most prescribed anticoagulants globally. Their strategy focuses on lifecycle management, label expansions, and real-world evidence generation to reinforce Eliquis's clinical superiority in PE and VTE management. Pfizer's expansive global commercialization network and BMS's clinical research capabilities create a formidable, vertically integrated competitive position.
Bayer AG - Xarelto (Rivaroxaban) Global Powerhouse
Bayer's Xarelto remains a top competitor with strong penetration across Europe, North America, and Asia-Pacific. Bayer consistently invests in post-marketing surveillance studies and direct-to-physician engagement programs that maintain prescriber loyalty. Their strategic expansion into emerging markets, particularly in Southeast Asia and Latin America, positions Xarelto to capture significant growth in fast-developing PE therapeutic markets.
Boehringer Ingelheim GmbH - Pradaxa (Dabigatran) and Pipeline Strength
Boehringer Ingelheim, the originator of the DOAC class with Pradaxa (dabigatran), continues to leverage its first-mover advantage while investing heavily in next-generation anticoagulants targeting Factor XI - a pathway that promises effective thrombosis prevention with substantially lower bleeding risk. Their clinical innovation agenda positions them as a critical player in the next chapter of pulmonary embolism treatment.
Market Segmentation Performance
Understanding which segments are driving the pulmonary embolism market helps decision-makers identify high-priority investment zones:
By Treatment Type:
Anticoagulants dominate, accounting for the largest revenue share - driven by widespread DOAC adoption across global geographies
Thrombolytics hold a significant clinical share in massive PE cases requiring rapid clot dissolution
Surgical embolectomy and catheter-directed procedures represent the fastest-growing segment, fueled by device innovation
By Diagnosis:
CT Pulmonary Angiography (CTPA) leads diagnostic revenue, supported by AI-enhanced imaging algorithms improving detection accuracy
Echocardiography and D-dimer testing retain significant clinical use across emergency settings
By End User:
Hospitals and critical care centers account for the majority of market revenue
Ambulatory surgical centers and specialty clinics are the fastest-growing end-user segment
By Region:
North America: Dominant region with the largest revenue share, driven by advanced healthcare infrastructure, high PE awareness, and rapid technology adoption
Asia-Pacific: Fastest-growing region - China, India, Japan, and South Korea are scaling up diagnostic capabilities and PE treatment protocols at an accelerating pace
TOC Summary:
The pulmonary embolism market is projected to grow from USD 2.66 billion in 2026 to USD 5.10 billion by 2033 at a CAGR of 10.3%, outpacing many adjacent cardiovascular therapeutic markets
North America holds the dominant regional share, accounting for over 40% of global revenue in 2025, anchored by the United States' high diagnostic rate and sophisticated PE response infrastructure
Asia-Pacific is the fastest-growing region, with China and India driving demand through expanding hospital networks and growing awareness of VTE as a critical public health issue
Anticoagulants - especially DOACs - represent the largest product segment by revenue, reshaping global PE treatment guidelines away from traditional warfarin therapy
Catheter-directed mechanical thrombectomy is the fastest-growing procedural segment, with devices from Inari Medical and Boston Scientific gaining rapid clinical adoption
Pfizer/BMS (Eliquis), Bayer (Xarelto), and Boehringer Ingelheim (Pradaxa) collectively command the majority of global anticoagulant market revenue in PE management
Artificial intelligence integration in CTPA imaging, risk stratification algorithms, and clinical decision support systems is accelerating early PE detection and improving patient outcomes
Geopolitical disruptions - including US-China trade tensions impacting API supply chains - and post-pandemic supply chain restructuring are prompting pharmaceutical companies to diversify manufacturing bases
Supply-demand dynamics are tightening as PE incidence rises with
global aging populations, while manufacturing capacity for novel anticoagulants remains concentrated among a small group of dominant playersEmerging competitors targeting Factor XI inhibitors and next-generation thrombolytics represent the most disruptive pipeline threat to incumbent market leaders over the next 5–7 years
🎯 Ready to Make a Strategic Move? Access the Complete Pulmonary Embolism Market Report Today
Buy Now → https://www.fortunedatavista.com/checkout/1102?payment_type=single
AI Impact: Transforming Pulmonary Embolism Diagnosis and Treatment
Artificial intelligence is no longer a future-state concept in pulmonary embolism care - it is an active and expanding clinical reality. AI-powered CTPA analysis tools are now deployed in leading academic medical centers across North America and Europe, identifying PE with diagnostic accuracy rivaling experienced radiologists while dramatically reducing reporting time from hours to minutes.
Beyond diagnostics, AI-driven clinical decision support platforms are integrating patient history, laboratory values, and imaging data to generate individualized risk stratification scores - enabling clinicians to determine the optimal treatment pathway for each patient, from outpatient anticoagulation to intensive catheter-directed intervention. Companies like Roche and GSK are employing predictive AI models for bleeding risk assessment, reducing adverse events and improving the economic value of PE management.
Machine learning algorithms are also being applied to drug discovery pipelines, accelerating the identification of novel anticoagulant targets and shortening clinical development timelines. The net effect is a market that is innovating at an unprecedented pace, creating significant opportunities for both pharmaceutical and digital health investors.
Geopolitical Impact on the Pulmonary Embolism Market
The global pulmonary embolism market does not operate in a geopolitical
vacuum. US-China trade tensions have introduced meaningful uncertainty into active pharmaceutical ingredient (API) supply chains, with a significant proportion of global API production concentrated in China and India. Pharmaceutical companies with heavy API sourcing dependence are actively restructuring supply chains through nearshoring, dual-sourcing strategies, and strategic inventory buffering to mitigate geopolitical risk.
Regulatory divergences between the FDA, EMA, and regulatory bodies in Asia-Pacific markets continue to create market access timing gaps, particularly for novel agents targeting emerging anticoagulant pathways. Geopolitical instability in the Middle East and select African markets constrains distribution networks and elevates counterfeit drug risks, limiting revenue capture in high-growth emerging markets.
Forward-looking organizations are responding through regulatory harmonization initiatives, regional manufacturing investments, and adaptive commercial strategies that account for geopolitical volatility as a standing market variable - not an exception.
Supply-Demand Analysis: A Market Under Constructive Tension
Demand for pulmonary embolism therapeutics is structurally rising. The global aging population - projected to reach 1.6 billion individuals aged 65+ by 2050 - represents an expanding at-risk cohort for PE, given that advancing age is one of the strongest independent risk factors for venous thromboembolism. Cancer-associated thrombosis, affecting approximately 20% of all VTE cases, represents another demand accelerator as cancer survival rates improve globally.
On the supply side, the DOAC market has matured rapidly, with multiple generics entering key markets following patent expiries on pioneering agents. This pricing pressure at the commodity end of the market is simultaneously driving innovation at the premium segment - with next-generation anticoagulants, mechanical thrombectomy devices, and digital PE management platforms commanding value-based pricing premiums.
Healthcare systems globally are increasingly adopting integrated PE care pathways - from emergency triage to post-discharge monitoring - creating demand for bundled therapeutic solutions that extend beyond individual drug products into comprehensive disease management ecosystems.
Key Players in the Global Pulmonary Embolism Market
Pfizer Inc. (United States)
Bristol-Myers Squibb Company (United States)
Bayer AG (Germany)
Boehringer Ingelheim GmbH (Germany)
Daiichi Sankyo Company, Limited (Japan)
Sanofi S.A. (France)
Johnson & Johnson (Janssen Pharmaceuticals) (United States)
Abbott Laboratories (United States)
Boston Scientific Corporation (United States)
Inari Medical, Inc. (United States)
Access the Full Intelligence Report
Decision-makers, investors, and strategy teams seeking granular market intelligence on therapeutic pipelines, regional revenue breakdowns, competitor benchmarking, and 2026–2033 growth projections can access the complete pulmonary embolism market report through the link below.
https://www.fortunedatavista.com/industry-analysis/pulmonary-embolism-market
About Us
Fortune Data Vista is a premier market intelligence and consulting company based in Texas with a branch office in India. We are known for mid and assisting firms using smart actionable data. We don't just offer surveys but we provide comprehensive strategies and professional guidance, thorough market analysis, and tailored reports to address and meet each client's factual and holistic needs.
Our research helps businesses comprehend market dynamics, assess the viability of new investments, identify growth avenues, and comprehend the market dynamics. Each report is meticulously tailored to align and target the organizational objectives while exploring new avenues in diverse international markets.
Media Contact
Fortune Data Vista
Houston, Texas, United States
Phone: +1 (917) 947–0251
Email: sales@fortunedatavista.com
Follow Us: LinkedIn | Facebook | Twitter | YouTube
This press release is intended for business, investment, and strategy audiences seeking current intelligence on the global pulmonary embolism market.
You May Also Like:
Where are the Untapped Opportunities in the Pulmonary Embolism Market?
What Makes the Pulmonary Embolism Market Attractive for Investors?
How Will Consumer Demand Shape the Future of the Pulmonary Embolism Market?
What Strategic Moves are Leading Companies Making in the Pulmonary Embolism Market?
What is the Future Outlook of the Pulmonary Embolism Market?
Top comments (0)